Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
ThesisIdorsia: the story is balanced — Clinical trial readouts for pipeline assets (selatogrel Phase 3 data for acute MI, cenerimod Phase 3 data for lupus…
★ Analysts see FY2027 revenue reaching $269M — +25.1% growth in a single year.
What Moves the Stock
01Clinical trial readouts for pipeline assets (selatogrel Phase 3 data for acute MI, cenerimod Phase 3 data for lupus, aprocitentan resistant hypertension data)
02QUVIVIQ commercial uptake metrics including prescription trends, formulary access wins, and quarterly revenue trajectory versus Street estimates
03Partnership or licensing deals that provide non-dilutive capital and validate pipeline asset value
04Regulatory submissions and approval decisions from FDA and EMA for pipeline candidates
05Cash runway updates and financing activities given negative free cash flow of $400M annually
06QUVIVIQ (daridorexant) insomnia treatment sales in US and European markets (estimated >80% of current revenue)
07Potential milestone payments and royalties from regional licensing partnerships
08Future revenue from pipeline assets upon approval (selatogrel, cenerimod, aprocitentan)
Watch on earnings: QUVIVIQ weekly prescription data (TRx and NRx trends from IQVIA or Symphony Health), Clinical trial enrollment rates and data readout timing for selatogrel, cenerimod, and aprocitentan Phase 3 programs, Quarterly cash burn rate and updated cash runway guidance.
One Sentence Summary:
Idorsia: the story is balanced — clinical trial readouts for pipeline assets (selatogrel phase 3 data for acute mi, cenerimod phase 3 data for lupus.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
